Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 3;28(10):1618-1622.
doi: 10.1093/ibd/izac052.

Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019-A Population-based Study

Mohamed Attauabi  1   2   3 , Jens Frederik Dahlerup  4 , Anja Poulsen  5 , Malte Rosager Hansen  6 , Marianne Kajbæk Vester-Andersen  7 , August Pilegaard Prahm  5 , Natalia Pedersen  8 , Lone Larsen  9 , Tine Jess  9   10 , Anders Neumann  11 , Kent V Haderslev  12 , Akbar Molazahi  13 , Anders Berg Lødrup  14 , Henning Glerup  15 , Asser Mathiassen Oppfeldt  16 , Michael Dam Jensen  17 , Klaus Theede  2   3 , Marianne Kiszka-Kanowitz  2   3 , Jakob Benedict Seidelin  1 , Johan Burisch  2   3
Affiliations

Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019-A Population-based Study

Mohamed Attauabi et al. Inflamm Bowel Dis. .
No abstract available

Keywords: COVID-19 outcomes; disease activity; inflammatory bowel diseases; population-based; sequelae.

Plain language summary

This brief report investigated the impact of clinical, biochemical, and endoscopic activity of IBD on the severity and long-term outcomes of COVID-19 in a prospective population-based cohort. The study did not identify any association between IBD activity and COVID-19 outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proportion of patients experiencing adverse and severe COVID-19 outcomes by (A) UC and (B) CD disease activity measures. Data are presented as unadjusted proportions. None of the patients with unknown clinical activity of UC experienced adverse or severe COVID-19.
See this image and copyright information in PMC

References

    1. Attauabi M, Dahlerup JF, Poulsen A, et al. Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases – a Danish prospective population-based cohort study with individual-level data. J Crohn’s Colitis. 2021;In press. - PMC - PubMed
    1. Ricciuto A, Lamb CA, Benchimol EI, et al. Inflammatory bowel disease clinical activity is associated with COVID-19 severity especially in younger patients. J Crohns Colitis. 2021:jjab172. doi:10.1093/ecco-jcc/jjab172 - DOI - PMC - PubMed
    1. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69(7):1213–1217. doi:10.1136/gutjnl-2020-321411 - DOI - PubMed
    1. Derikx LAAP, Lantinga MA, De Jong DJ, et al. Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohn’s Colitis. 2021;15(4):529–539. doi:10.1093/ecco-jcc/jjaa215 - DOI - PMC - PubMed
    1. Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS. Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease. Gastroenterology. 2020;159(4):1541–1544.e2. doi:10.1053/j.gastro.2020.05.066 - DOI - PMC - PubMed